The question of whether tumorigenic cancer stem cells exist in human melanomas has arisen in the last few years 1 . Here we show that in melanomas, tumour stem cells (MTSCs, for melanoma tumour stem cells) can be isolated prospectively as a highly enriched CD271 1 MTSC population using a process that maximizes viable cell transplantation 1,2 . The tumours sampled in this study were taken from a broad spectrum of sites and stages. Highviability cells isolated by fluorescence-activated cell sorting and re-suspended in a matrigel vehicle were implanted into T-, B-and natural-killer-deficient Rag2 2/2 cc 2/2 mice. The CD271 1 subset of cells was the tumour-initiating population in 90% (nine out of ten) of melanomas tested. Transplantation of isolated CD271 1 melanoma cells into engrafted human skin or bone in Rag2 2/2 cc 2/2 mice resulted in melanoma; however, melanoma did not develop after transplantation of isolated CD271 2 cells. We also show that in mice, tumours derived from transplanted human CD271 1 melanoma cells were capable of metastatsis in vivo. CD271 1 melanoma cells lacked expression of TYR, MART1 and MAGE in 86%, 69% and 68% of melanoma patients, respectively, which helps to explain why T-cell therapies directed at these antigens usually result in only temporary tumour shrinkage.
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Cancers derive by clonal progression to appear as abnormal growths. At diagnosis, they can be at a stage ranging from low risk of metastasis and probable cure, to highly aggressive with a marked tendency for metastasis. We previously proposed that at early stages, the self-renewing, minority tumorigenic population can differentiate non-malignant progeny, and at later stages the self-renewing cancer cell population may become the dominant population in a tumour [3] [4] [5] . Identification of cancer stem cells in solid tumours 2, 4, [6] [7] [8] [9] provided evidence that cancer stem cells seem to recapitulate the developmental program of corresponding normal tissue stem or progenitor cells, although in an incomplete and disorganized manner 10 . Malignant melanomas, like normal melanocytes, derive from the neural crest lineage 11 . The prospective isolation of mammalian neural crest stem cells was achieved by sorting for the CD271 cell subset 12 . Expression of CD271 has been found in a number of human neural-crest-derived tissues and in some human cancers, including melanomas 13, 14 . Therefore, we searched for melanoma tumour-initiating cells by testing surgical patient samples with monoclonal antibody to CD271 as well as with monoclonal antibodies to other cell-surface antigens involved in maturation of melanocytes and/or melanoma development ( Supplementary Table 1 ).
Melanomas can quickly progress from localized cutaneous disease to regional lymph node and more advanced visceral metastasis. A broad spectrum of freshly resected melanomas that included primary cutaneous lesions as well as nodal, in-transit and cutaneous metastasis (Supplementary Table 2 ) was used to profile the expression of CD271 and other candidate MTSC markers by fluorescence-activated cell sorting (FACS). After analysing multiple samples, we found that CD271 was the most reliable cell-surface molecule in distinguishing heterogeneous populations within melanomas ( Supplementary Table 1 ). CD271 was found to be heterogeneously expressed in nine out of ten melanomas analysed, comprising between ,2.5% to ,41% (mean 5 16.7%) of the total cell population ( Supplementary Fig. 1 ).
To assess the presence of MTSCs and to avoid factors that could allow selection of the most aggressive tumour subsets during passaging, our cells were isolated directly from surgical patient samples and transplanted using the recently reported melanoma in vivo transplantation assay 1 (see Methods and Supplementary Information). Notably, we found that the CD271 1 cell population isolated directly from six different patients and transplanted into Rag2 2/2 cc 2/2 mice resulted in melanomas at a markedly higher rate as compared to CD271 2 or Lin 2 (bulk population) cells obtained from the same tumour ( Fig. 1 , Supplementary Figs 2-4 and Supplementary Table 3 ). In doses ranging from 10 to 10 5 cells, CD271 1 cells engrafted in 70% (26 out of 37) of the transplants compared to 7% (3 out of 41) of CD271 2 (P , 0.0001) and 16% (5 out of 30) of Lin 2 cells (P , 0.0001). Some melanomas were too small for direct analysis, and in these cases pieces of freshly resected tumour were transplanted subcutaneously onto the back of Rag2 2/2 cc 2/2 mice (Xeno P0, n 5 3). Alternatively, xenografts were established from cells amplified in vitro for 1-2 passages (Xeno Pi, n 5 2) after being isolated from patient tumours. CD271 1 expression in xenografted tumours varied from 6.4% to 75.3% (mean 5 26.3%) of the total cell population ( Supplementary Fig. 5 ). The CD271 1 population isolated from xenografted tumours engrafted growing melanomas in 72% of CD271 1 cell injections (26 out of 36) compared to 20% tumour engraftment from CD271 2 cells (5 out of 25) (P 5 0.0001) ( Table 1 and Supplementary Figs 6a and 7-9).
Furthermore, we wished to determine whether newly identified ( Supplementary Fig. 10 ). We tested whether the CD271 1 and/or the CD271 2 cells from xenografts representing two different patients were able to secondarily transplant melanoma in vivo: 72.2% (13 out of 18) of the samples of CD271 1 cells engrafted growing melanomas, compared with 27.7% (5 out of 18) for CD271 2 cells (P 5 0.009), in cell doses ranging from 10 to 5 3 10 3 injected cells ( Supplementary Fig.  6b ). Altogether, CD271 1 melanoma cells isolated from xenografted samples engrafted at 72% (39 out of 54) compared with 23% (10 out of 43) for CD271 2 cells (P , 0.0001) ( Table 2) , which required higher cell doses and longer latency. 
, CD271 1 and C271 2 cells from the Mel114 patient sample; CD271 1 but not CD271 2 melanoma cells induce tumours upon intradermal injection in 30% matrigel into B-, T-and NK-cell-deficient Rag2 2/2 cc 2/2 mice after 28-32 weeks. SSC, side scatter. b, Summary table of tumour formation frequencies by CD271 1 and CD271 2 human melanoma cells isolated from all patients. 20% (5 of 25)* Data shown are for xenografted samples (P0, surgically removed human tumour that was implanted into Rag2 2/2 cc 2/2 mice; Pi, surgically removed human tumour that was expanded in vitro for 1-2 passages and injected into Rag2 2/2 cc 2/2 mice). Rag2 2/2 cc 2/2 mice were injected with live mLin 2 (H2-Kd 2 /mCD45.2 2 /mTer119 2 ), CD271 1 and CD271 2 melanoma cells isolated by FACS and mixed with matrigel. Numbers indicate the ratio of tumour incidence relative to the number of injections. * P 5 0.0001. a, Humanized Rag2 2/2 cc 2/2 mice that contained skin grafts from the same healthy donor were used to assess the tumorigenic potential of CD271 1 cells. Dermal melanoma xenograft (P0) from a primary patient (Mel43) was used to purify live mouse Lin 2 (mLin 2 ; H2-Kd 2 /mCD45.2 2 /mTer119 2 ), CD271 1 and CD271 2 melanoma cells by FACS and then cells were injected into separate human skin grafts on Rag2 2/2 cc 2/2 mice from the same healthy donor. Left: human skin graft of Rag2 2/2 cc 2/2 mice 28 weeks after injection of 2 3 10 4 CD271 2 cells. Right: melanoma formation in human skin graft of Rag2 2/2 cc 2/2 mice 28 weeks after injection of 2 3 10 4 of CD271 1 cells. b, Surgically resected primary melanoma from patient Mel826 was used to isolate live hLin 2 , CD271 1 and CD271 2 cells by FACS and then cells were injected into separate human skin grafts on Rag2 2/2 cc 2/2 mice from the same healthy donor. Left: human skin graft 16 weeks after injection of 2 3 10 4 CD271 2 cells. Middle and right: melanoma tumour formation and lung metastasis 16 weeks after injection of 6 3 10 3 CD271 1 cells. c, Surgically resected melanoma adjacent to the patella from patient Mel210 was used to purify live hLin 2 , CD271 1 and CD271 2 melanoma cells by FACS; 10 3 cells of each highly purified fraction were then injected separately into two NSG mice subcutaneously near the grafted human bone fragment. Left: human bone graft of NSG mice 20 weeks after injection of 10 3 CD271 2 cells. Right: human bone graft of NSG mice 20 weeks after injection of 10 3 CD271 1 cells.
Our tumorigenic assays with surgical and xenograft transplanted melanomas described above provide strong evidence that in most patients MTSCs occur in the CD271 1 fraction, which are able not only to induce tumours but also to re-establish the original CD271 expression heterogeneity of the primary tumour. However, we observed an increase in combined engraftment efficiency of CD271 2 cells isolated from xenopassaged melanomas compared to the combined engraftment frequency of CD271 2 cells isolated from surgical samples ( Table 2 ). In addition, in our experiments with established melanoma cell lines we determined that unfractionated cells were able to engraft at 100% frequencies from as little as ten cells ( Supplementary Fig. 11 ). These results indicate that melanoma cells kept for prolonged periods of time in vitro as cell cultures or in vivo as passaged xenografts continue to undergo malignant progression, such that successful subclones emerge, in some samples independent of their cell-surface immunophenotype. Additional experiments would be required to understand the precise molecular mechanisms underlying the tumorigenic evolution of cells during their passaging in vitro or in vivo, and their relationship to the patient's tumour.
Furthermore, we wished to determine whether MTSCs can be identified in the context of a more physiologically relevant human tissue microenvironment. We therefore created humanized mice by grafting fragments of normal human skin or bone onto the back of Rag2 2/2 cc 2/2 and NOD-SCID/IL-2 rc null (NSG) mice (see Supplementary Information). CD271 1 cells, but not CD271 2 cells, isolated from two independent primary dermal melanomas (Mel43 and Mel826) induced tumours in the human skin grafts ( Fig. 2a, b) . Similarly, CD271 1 cells, but not CD271 2 cells, isolated from melanoma adjacent to the patella (Mel210) formed a tumour in an NSG mouse grafted with human bone fragment ( Fig. 2c ). The poor survival rate of melanoma patients diagnosed with advanced stages is due to the high metastatic potential of this cancer that rapidly invades lungs, liver, brain and other organs. Organ analysis of the humanized mouse injected intradermally with CD271 1 cells derived from a patient sample (Mel826) revealed that these cells had metastasized into the lungs and caused formation of metastatic nodules (Fig. 2b) . In vivo intradermal tumorigenic assays of melanomas surgically removed from two additional patients (Mel1119 and Mel213) demonstrated that tumours formed by CD271 1 cells have the ability to form metastases in the liver (Supplementary Fig. 2b ) and lungs of mice ( Supplementary Fig. 4a, b) , whereas neither tumours nor metastases were observed in matching mice injected with CD271 2 cells isolated from the same patients. These results show that CD271 1 MTSCs give rise to a cell population in the tumour capable of metastasis. Expression of CD271 in primary melanomas has been previously associated with perineural invasion 15 ; in addition, other groups have shown that CD271 and its ligand NGF can regulate invasive properties of metastatic melanoma cell lines in vitro 16, 17 . Further studies will be required to elucidate the precise molecular mechanisms driving metastatic progression of CD271 1 cells in vivo.
Percentage of CD271 + tumour cells expressing MTAs
Pioneering studies of T-cell immunity to melanoma antigens 18, 19 have led to immunotherapy trials 20 . Multiple immunotherapies based on the well defined melanoma tumour antigens such as tyrosinase, MART1 (also called melan-A) and others have had limited success in melanoma patients 21, 22 . Our immunohistochemistry expression analysis of Mel327, Mel525 and Mel425 tumour sections with CD271 monoclonal antibody and with melanoma tumour antigen monoclonal antibody cocktail (TYR/MART1/HMB-45) revealed that the CD271 1 cells driving melanoma progression lack expression of those markers (Fig. 3a) . At the same time MAGE family proteins (MAGEC1/ MAGEC2) were found to be expressed on a higher fraction of CD271 1 cells ( Supplementary Fig. 14) of the same patients. Next, we used melanoma tissue arrays to individually assess the expression of melanoma tumour antigens (TYR, MART1, MAGEC1 and MAGEC2) and CD271 in multiple melanoma patients. In 86% (42 out of 49), 69% (31 out of 45) and 68% (28 out of 41) of melanoma patients, CD271 1 tumour cells either completely or partially lacked expression of TYR, MART1 and MAGEC1/MAGEC2, respectively (Fig. 3b-d and Supplementary Figs 15-17) . These results uncover possible limitations of existing melanoma immunotherapies, and can be used to argue in favour of new approaches that will be directed at all MTSCs in a tumour, as well as their progeny.
In this study, the neural crest stem cell marker CD271 was implicated as a cancer stem cell marker, allowing identification and prospective isolation of melanoma cancer stem cells. Previous studies on human melanoma have found several candidate markers that unequivocally identify within the tumour a cancer stem cell population 23, 24 . A recent report 1 using principally metastatic melanoma cells isolated either from patients' lymph nodes or from tumours passaged by serial xenografts in mice revealed frequencies of ,1 in 2 to ,1 in 8 cells that are tumour initiating. On the basis of that study it has been claimed that there are no cancer stem cells in melanoma, and that all cells in a cancer may be equally tumorigenic [25] [26] [27] . Our data, based on transplantation of a broad spectrum of both primary and advanced-stage melanomas, contradict those conclusions. Importantly, differences in MTSC frequencies are not due to the mouse strains used (Rag2 2/2 cc 2/2 versus NSG), as revealed in our direct comparison of their tumour cell engraftment sensitivity ( Supplementary Fig. 13 ). Studies of haematopoietic cancers have found that a continuous selection of more malignant cell subsets occurs 28, 29 and that it might be triggered by oncogenic mutations affecting early stages of haematopoietic stem cell differentiation 30 . This opens up the possibility that during cancer progression the entire tumour may be made up of less aggressive and of more aggressive malignant clones. The extreme of this view is that some subclones may emerge (either as a result of passaging or disease progression) that largely or completely fail to differentiate non-tumorigenic subsets. This view could reconcile the data presented here with a previous report 1 . Melanomas are intrinsically extremely aggressive tumours and can quickly undergo tumorigenic evolution towards more malignant stages. Our data are consistent with the possibility that some metastatic melanomas may have very high frequencies of tumorigenic cells (for example, in Mel415l; Supplementary Fig. 12 ) similar to the rare outlier cases in other cancers 4 . The most crucial test of the tumour stem cell hypothesis is that markers or pathways restricted to tumour stem cells can be targets for curative therapies in the patient, which has not yet been done. Conversely, therapies targeting markers on the progeny of tumour stem cells, but not on tumour stem cells themselves, should be less efficient. Melanoma tumour antigens (TYR, MART1, MAGEC1/MAGEC2) used during induced or adoptive T-cell immune responses are expressed at high frequencies on CD271 2 cells, ( Supplementary Fig. 18 ) but are either completely or partially lacking on the CD271 1 cells of the significant proportion of melanoma patients analysed. Existing immunotherapies fail to eradicate melanomas completely 19, 20 , perhaps because all MTSCs also need to be eliminated. Identification of MTSCs by their cell-surface immunophenotype may allow patient-by-patient selection for more efficient immunotherapies and/or drugs to be tested in clinical trials.
METHODS SUMMARY
Tumour tissues were digested into single-cell suspension as previously described 2, 7, 9 . Tumour cell suspensions were stained with anti-human CD271 antibodies directly conjugated to Biotin (557195 BD Pharmingen) or Alexa Fluor 647 (560326 BD Pharmingen) and a human lineage cocktail of monoclonal antibodies directly or custom conjugated to pacific blue: anti-CD45 (4528 Invitrogen), CD2 (555324 BD Pharmingen), CD3 (555329 BD Pharmingen), CD31 (303114 Biolegend); in the case of xenografted tumours the following antibodies to mouse lineage markers were used: H2Kd (553565 BD PharMingen), CD45.2 (109820 Biolegend) and mTer119 (557915 BD PharMingen) directly conjugated to pacific blue or FITC. All antibodies were used in a 1:50 dilution except H2Kd (1:100) to allow separation of mouse cells. Propidium iodide was used to exclude non-viable cells. Flow cytometry analysis and cell sorting was performed on a BD FACSAria (Becton Dickinson) under 20 psi with a 100-mm nozzle.
During FACS isolation of candidate MTSC populations we adopted the strategy of setting up negative and positive sort gates at least one log apart to prevent cross-contamination between negative and positive cell fractions that might occur when weakly positive cells (CD271 low ) cannot be distinguished from negative cells with a high degree of probability. FACS-sorted tumour cells were counted in a haemocytometer (Hausser Scientific) and graded numbers of cells were suspended in a volume of 50 ml of media containing 30% standard matrigel (354234 BD Pharmingen). Suspension was then injected by 31-gauge insulin syringes (Becton Dickinson) intradermally on the flank of B-, T-and NK-celldeficient 4-8-week-old Rag2 2/2 cc 2/2 mice anaesthetized with isoflurane-O 2 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Tumour specimens were provided by Stanford University hospital after obtaining the informed consent. Experiments were conducted on Rag2 2/2 cc 2/2 (double knockout) mice in accordance with guidelines established by the SU Administrative Panels for Lab Animal Care. Primary tumour implantation. Rag2 2/2 cc 2/2 mice were anaesthetized with isoflurane-O 2 and small pieces (,2 mm) of fresh tumour were implanted on both sides of the flank. The incision was sealed with surgical staple. Tumour digestion. Tumours were minced with a razor blade, and then placed in a solution of liberase blendzymes 2 and 4 (Roche) in Media 199 (Invitrogen) at 37 uC for up to 3 h to allow complete cell dissociation with pipetting every 30 min. Cells were filtered through 40 mm nylon mesh, treated with LCK buffer to eliminate erythrocytes and washed twice with HBSS/2% heat inactivated calf serum (HICS). Cells were stained for flow cytometry or injected into mice as whole-tumour single-cell suspensions. Analysis and cell separation by flow cytometry. The single-cell suspensions were washed in HBSS/2% HICS and counted and then re-suspended in 100 ml per 10 6 cells of HBSS and incubated with 1 mg ml 21 sandoglobin for 10 min. The suspensions were then washed with HBSS/2% HICS, re-suspended in 100 ml per 10 6 cells of HBSS, and stained with antibodies. Anti-CD271 (biotin conjugated BD Pharmigen 557195, or Alexa-Fluor647-conjugated BD Pharmingen 560326) at a 1:50 dilution; lineage markers diluted at 1:50 anti-CD45, anti-CD2, anti-CD3, anti-CD31 directly or custom conjugated to pacific blue were used to allow identification of contaminating non-tumour cells from patient samples. Tumours that had been passaged in the mouse were incubated with anti-H2k d (diluted 1:100; BD Pharmingen) anti-mCD45.2 and mTer119. Antibodies were directly conjugated to Pacific Blue or FITC; stained cells were washed and resuspended at 0.5 ml per 10 6 cells with Hoechst 33342 or propidium iodide to allow exclusion of non-viable cells. Flow cytometry analysis and cell sorting was performed on a BD FACSAria (Becton Dickinson) under 20 psi with a 100-mm nozzle.
Single-cell suspension injections. FACS-sorted tumour cells were counted in a haemocytometer (Hausser Scientific) and graded numbers of cells were suspended in a volume of 50 ml of media containing 30% standard Matrigel (354234 BD Pharmingen). Suspension was then injected by 31-gauge insulin syringes (Becton Dickinson) intradermally on the flank of B-, T-and NK-celldeficient 4-8-week-old Rag2 2/2 cc 2/2 mice anaesthetized with isoflurane-O 2 . Humanized mice models. For the generation of Rag2 2/2 cc 2/2 mice with grafted human skin, briefly, full thickness human skin sample was obtained under signed consent from patients undergoing breast reduction, abdominoplasty or face lift. Adult mice were anaesthetized by inhalation of 2% isoflurane in 100% oxygen at a flow rate of 2 l min 21 . The dorsum of the mouse was shaved with an electric clipper and then treated with a depilatory agent to remove the hair completely. After sterile preparation, a rectangular area of approximately 1-1.5 cm by 1-1.5 cm of skin was resected, leaving the panniculus carnosus intact. Human skin graft was sutured in place with 6-0 prolene and covered with a non-adhesive dry dressing. Mice are then allowed to recover from anaesthesia in a warm chamber then housed individually in separate cages.
For the generation of NSG mice with grafted human bone, briefly, bones from human abortuses were obtained from Advanced Bioscience Resources, Inc. Adult mice were anaesthetized by inhalation of 2% isoflurane in 100% oxygen at a flow rate of 2 l min 21 . A small patch of fur was shaved, and a small (2 mm) incision made in the skin. A pair of blunt forceps was used to generate a small pocket underneath the skin and a small (5 mm) piece of aborted long bone was inserted into the pocket. The incision was closed with a single wound clip. A 10 ml volume of 2% lidocaine:1/100,000 epinephrine was applied to the wound site, which provides analgesic for a period of 2 h. Mice are then allowed to recover from anaesthesia in a warm chamber then housed individually in a separated cage. Tissue immunofluorescence. A small piece of tumour specimen was kept aside and frozen in optimal cutting temperature (OCT) embedding media. Sections of 7 mm were cut, fixed in ice-cold acetone for 4 min, and air dried. Slides were then rinsed in PBS, and blocked in PBS with 1% BSA, 5% goat serum (for extracellular antigens) and 1% BSA, 5% goat serum and 0.01% Triton X-100 (for intracellular antigens) for 30 min. We used the following primary antibodies: rat anti-human CD271 (27005 Abcam), Pan Melanoma cocktail (mixture of mouse anti-human tyrosinase, -MART1 and -HMB-45 antibodies; CM165B Biocare Medical) and anti-human MAGEC1/C2, a gift of L. Cohen. Sections were incubated with the primary antibody diluted in blocking solution overnight at 4 uC, washed in PBS, followed by secondary antibody (goat anti-rat AlexaFluor 594 and goat antimouse AlexaFluor 488 (Molecular Probes)) incubation for 1 h at room temperature. Slides were again washed, incubated with Hoechst 33342 (Invitrogen) for 3 min, rinsed in PBS, and coverslipped with Fluoromount G (Southern Biotech). Staining was analysed under a LeicaDM4000B microscope. Pictures were taken under 340 objective and scale bars are equal to 50 mm. Melanoma tissue array immunostaining. Paraffin melanoma tissue array slides (US Biomax Inc.) containing 80 1.5-mm tissue cores from primary and metastatic melanoma patients were de-paraffinized through three changes of xylene, incubating 10 min in each change. Slides were hydrated to water by dipping them 20-30 times in each of two changes of 100% ethanol, two changes of 95% ethanol, one of 80% ethanol, one of 70% ethanol, and two changes of distilled water. Slides were placed in a microwave, covered with 50 mM Tris/20 mM EDTA pH 9.0 buffer and microwaved for 15 min. Slides were cooled for 30 min, rinsed in distilled water twice and once in PBS for 5 min. Three tissue array slides were stained each with the following antibody combination: CD271 (Abcam ab3125 R5) 1:100 and TYR (Novacastra NCL-L-TYROS) 1:20; CD271 1:100 and MART1 (Biocare CM077) 1:400; CD271 1:100 and MAGE (Abcam ab60049) 1:50 for 45 min at room temperature. Slides were washed for 15 min in PBS. The following fluorescent secondary antibodies at 1:100 were used to visualize each antigen: goat anti-mouse IgG1_AF594 for CD271, goat anti-mouse IgG2a_AF647 for TYR, goat anti-rabbit_AF647 for MAGE, goat anti-mouse IgG2b_AF647 for MART1. Slides were incubated in the dark for 45 min. Slides were washed for 15 min in PBS and mounted in fluorescent mounting medium containing DAPI (ProLong anti-fade reagent with DAPI, Invitrogen P36935). Slides were scanned and photographed at 320 using a Zeiss AxioImager motorized upright fluorescent microscope using appropriate filters for each fluorochrome.
